In this issue:
Venetoclax trials compared with chemoimmunotherapy
HSCT vs non-HSCT therapy for CTCL
Quizartinib in FLT3-positive AML patients
Ivosidenib maintenance post HSCT
Axi-cel treatment for R/R DLBCL patients
Efficacy and safety of sugemalimab
Inotuzumab-ozogamicin with or without blinatumomab
Clinical PET model performance
Durability of allogeneic HSCT
Comparison of BrECADD and eBEACOPP therapies
Please login below to download this issue (PDF)